Quality of life and psychosocial and physical well-being among 1,023 women during their first assisted reproductive technology treatment: secondary outcome.

Slides:

Advertisements

Similar presentations

Lisa Marii Cookingham, M. D. , Rachel P. Goossen, B. A. , Amy E. T

Advertisements

The effectiveness of gonadotropin-releasing hormone antagonist in poor ovarian responders undergoing in vitro fertilization: a systematic review and meta-analysis

Is the type of gonadotropin-releasing hormone suppression protocol for ovarian hyperstimulation associated with ectopic pregnancy in fresh autologous.

A giant oocyte in a cohort of retrieved oocytes: does it have any effect on the in vitro fertilization cycle outcome? Ronit Machtinger, M.D., Joseph.

Gonadotropin-releasing hormone agonist trigger in oocyte donors co-treated with a gonadotropin-releasing hormone antagonist: a dose-finding study Thi.

Luteal-phase ovarian stimulation is feasible for producing competent oocytes in women undergoing in vitro fertilization/intracytoplasmic sperm injection.

Oral contraceptive pretreatment significantly reduces ongoing pregnancy likelihood in gonadotropin-releasing hormone antagonist cycles: an updated meta-analysis

Patient and cycle characteristics predicting high pregnancy rates with single-embryo transfer: an analysis of the Society for Assisted Reproductive Technology.

Can pregnancy rate be improved in gonadotropin-releasing hormone (GnRH) antagonist cycles by administering GnRH agonist before oocyte retrieval? A prospective,

Samuel Santos-Ribeiro, M. D. , Johannie Siffain, M. D. , Nikolaos P

Triggering with human chorionic gonadotropin or a gonadotropin-releasing hormone agonist in gonadotropin-releasing hormone antagonist-treated oocyte donor.

A prospective, randomized, double-blinded study of assisted hatching in women younger than 38 years undergoing in vitro fertilization Andrea R. Hagemann,

1,500 IU human chorionic gonadotropin administered at oocyte retrieval rescues the luteal phase when gonadotropin-releasing hormone agonist is used for.

Administration of a gonadotropin-releasing hormone antagonist during the 3 days before the initiation of the in vitro fertilization/intracytoplasmic sperm.

Effect of a very-low-calorie diet on in vitro fertilization outcomes

Dennis J. Hand, Ph. D. , Vanessa L. Short, Ph. D. , M. P. H. , Diane J

Zhi-Yong Yang, M.D., Ri-Cheng Chian, Ph.D. Fertility and Sterility

Contrasting patterns in in vitro fertilization pregnancy rates among fresh autologous, fresh oocyte donor, and cryopreserved cycles with the use of day.

A randomized assessor-blind trial comparing highly purified hMG and recombinant FSH in a GnRH antagonist cycle with compulsory single-blastocyst transfer

Can an educational DVD improve the acceptability of elective single embryo transfer? A randomized controlled study Nicole Hope, M.B., B.S., Hon., Luk.

Comparison of fallopian tube sperm perfusion and intrauterine tuboperitoneal insemination: a prospective randomized study Leonidas Mamas, M.D., Ph.D.

The influence of female and male body mass index on live births after assisted reproductive technology treatment: a nationwide register-based cohort study

Follicle-stimulating hormone administered at the time of human chorionic gonadotropin trigger improves oocyte developmental competence in in vitro fertilization.

The relative contribution of assisted reproductive technologies and ovulation induction to multiple births in the United States 5 years after the Society.

Live birth of twins derived from zona-free oocytes

Grant D.E. McWilliams, D.O., John L. Frattarelli, M.D.

Randomized, controlled pilot trial of natural versus hormone replacement therapy cycles in frozen embryo replacement in vitro fertilization Ginny Mounce,

Mikkel Rosendahl, M. D. , Claus Yding Andersen, D. M. Sc

Improved monofollicular ovulation in anovulatory or oligo-ovulatory women after a low- dose step-up protocol with weekly increments of 25 international.

Effect of prolonged gonadotropin-releasing hormone agonist therapy on the outcome of in vitro fertilization-embryo transfer in patients with endometriosis

Subtle progesterone rise on the day of human chorionic gonadotropin administration is associated with lower live birth rates in women undergoing assisted.

Association of a single dose of gonadotropin-releasing hormone antagonist with nitric oxide and embryo quality in in vitro fertilization cycles Tsung-Hsien.

Establishing a human chorionic gonadotropin cutoff to guide methotrexate treatment of ectopic pregnancy: a systematic review Seema Menon, M.D., John.

Lisa Marii Cookingham, M. D. , Rachel P. Goossen, B. A. , Amy E. T

Robert F. Casper, M.D. Fertility and Sterility

Influence of acupuncture stimulation on pregnancy rates for women undergoing embryo transfer Caroline Smith, Ph.D., Meaghan Coyle, B.Hlth.Sc. (Acup.),

Prevention of in vitro fertilization twins should focus on maximizing single embryo transfer versus twins are an acceptable complication of in vitro fertilization

Ultrashort flare gonadotropin-releasing hormone (GnRH) agonist/GnRH antagonist protocol: a valuable tool in the armamentarium of ovulation induction for.

Comparison of luteal estradiol patch and gonadotropin-releasing hormone antagonist suppression protocol before gonadotropin stimulation versus microdose.

The effectiveness of gonadotropin-releasing hormone antagonist in poor ovarian responders undergoing in vitro fertilization: a systematic review and meta-analysis

How to improve the probability of pregnancy in poor responders undergoing in vitro fertilization: a systematic review and meta-analysis Dimitra Kyrou,

Venous thromboembolism in relation to in vitro fertilization: an approach to determining the incidence and increase in risk in successful cycles Karin.

Treatment of Ovarian Hyperstimulation Syndrome Utilizing a Dopamine Agonist and Gonadotropin Releasing Hormone antagonist N. Rollene, M. Amols, S. Hudson,

Prolonging oocyte in vitro culture and handling time does not compensate for a shorter interval from human chorionic gonadotropin administration to oocyte.

Gonadotropin-releasing hormone antagonist use is associated with increased pregnancy rates in ovulation induction–intrauterine insemination to in vitro.

Melatonin supplementation during controlled ovarian stimulation for women undergoing assisted reproductive technology: systematic review and meta-analysis.

Efficacy and safety of human chorionic gonadotropin for follicular phase stimulation in assisted reproduction: a systematic review and meta-analysis

Efficiency of changing the embryo transfer time from day 3 to day 2 among women with poor ovarian response: A prospective randomized trial Mustafa Bahceci,

Aaron K. Styer, M. D. , Diane L. Wright, Ph. D. , H. C. L. D. , Anne M

Live babies born per oocyte retrieved in a subpopulation of oocyte donors with repetitive reproductive success J. Ryan Martin, M.D., Jason G. Bromer,

Treatment of ovarian hyperstimulation syndrome using a dopamine agonist and gonadotropin releasing hormone antagonist: a case series Nanette L. Rollene,

Cameron Gilbert, M. Sc. , Maria Valois, M. D. , FRCPC, Ph. D

Are endometrial parameters by three-dimensional ultrasound and power Doppler angiography related to in vitro fertilization/embryo transfer outcome? Luis.

Antimüllerian hormone in gonadotropin releasing-hormone antagonist cycles: prediction of ovarian response and cumulative treatment outcome in good-prognosis.

Effect of gonadotropin-releasing-hormone-induced hypogonadism on insulin action as assessed by euglycemic clamp studies in men Subodhsingh Chauhan, M.D.,

Reducing the dose of human chorionic gonadotropin in high responders does not affect the outcomes of in vitro fertilization David W. Schmidt, M.D.,,

Follicular phase serum levels of luteinizing hormone do not influence delivery rates in in vitro fertilization cycles down-regulated with a gonadotropin-releasing.

Effects of gonadotropin-releasing hormone agonist/recombinant follicle-stimulating hormone versus gonadotropin-releasing hormone antagonist/recombinant.

Cost-effectiveness comparison between pituitary down-regulation with a gonadotropin- releasing hormone agonist short regimen on alternate days and an antagonist.

David H. Barad, M.D., M.S., Norbert Gleicher, M.D.

Transfer of two versus three embryos in women less than 40 years old undergoing frozen transfer cycles Inna Berin, M.D., Lawrence L. Engmann, M.D., Claudio.

Evaluating the role of exogenous luteinizing hormone in poor responders undergoing in vitro fertilization with gonadotropin-releasing hormone antagonists

Microdose gonadotropin-releasing hormone agonist in the absence of exogenous gonadotropins is not sufficient to induce multiple follicle development

A novel “delayed start” protocol with gonadotropin-releasing hormone antagonist improves outcomes in poor responders Hakan Cakmak, M.D., Nam D. Tran,

A randomized controlled trial of increasing recombinant follicle-stimulating hormone after initiating a gonadotropin-releasing hormone antagonist for.

Randomized, controlled pilot trial of natural versus hormone replacement therapy cycles in frozen embryo replacement in vitro fertilization Ginny Mounce,

Ovarian hyperstimulation syndrome prevention by gonadotropin-releasing hormone agonist triggering of final oocyte maturation in a gonadotropin-releasing.

In vitro viability and secretory capacity of human luteinized granulosa cells after gonadotropin-releasing hormone agonist trigger of oocyte maturation

Oocyte retrieval timing based on spontaneous luteinizing hormone surge during natural cycle in vitro fertilization treatment Daniel Bodri, M.D., M.Sc.,

Not all twins are monozygotic after elective single embryo transfer: analysis of 32,600 elective single embryo transfer cycles as reported to the Society.

Presentation transcript:

Quality of life and psychosocial and physical well-being among 1,023 women during their first assisted reproductive technology treatment: secondary outcome to a randomized controlled trial comparing gonadotropin-releasing hormone (GnRH) antagonist and GnRH agonist protocols Mette Toftager, M.D., Ph.D., Randi Sylvest, M.Sc., Lone Schmidt, M.D., Ph.D., D.M.Sc., Jeanette Bogstad, M.D., Kristine Løssl, M.D., Ph.D., Lisbeth Prætorius, M.D., Anne Zedeler, Ph.D., Thue Bryndorf, M.D., D.M.Sc., Anja Pinborg, M.D., D.M.Sc. Fertility and Sterility Volume 109, Issue 1, Pages 154-164 (January 2018) DOI: 10.1016/j.fertnstert.2017.09.020 Copyright © 2017 American Society for Reproductive Medicine Terms and Conditions

Figure 1 An overview of all subjects who started gonadotrophin stimulation in their first assisted reproductive technology cycle after randomization to either short gonadotropin-releasing hormone (GnRH) antagonist or long GnRH agonist protocol. The questionnaire on self-reported physical health was completed four times at: baseline (visit 0), at the day of oocyte retrieval (visit 1), 3 days after embryo transfer (visit 2), and the day of the pregnancy test 13-15 days after embryo transfer (visit 3). The quality of life questionnaire was completed at visit 3, but before the human chorionic gonadotropin result was known. If the woman did not have an embryo transfer, the questionnaire was completed at visit 2. Fertility and Sterility 2018 109, 154-164DOI: (10.1016/j.fertnstert.2017.09.020) Copyright © 2017 American Society for Reproductive Medicine Terms and Conditions